

April 18, 2018

To whom it may concern:

Company Name	TOHO HOLDINGS CO., LTD.
Corporate Representative	Norio Hamada, Chairman of the Board and Representative Director (First Section of Tokyo Stock Exchange Securities Code:8129)
Contact:	Makoto Kawamura, Corporate Officer, General Manager, Public and Investor Relations Department (TEL: 81-3-6838-2803)

Announcement about Capital Alliance with AMBICION Co., Ltd.

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Chairman of the Board and Representative Director: Norio Hamada; hereinafter, "TOHO HOLDINGS") announces today it has decided to subscribe to the third-party share issuance by AMBICION Co., Ltd. (Headquarters: Tokyo; CEO: Yoshiyuki Saito; hereinafter, "AMBICION"), a bio venture company. Specifics are as outlined below:

1. Reason for capital alliance

TOHO HOLDINGS is a corporate group active in medical, nursing and healthcare fields, engaged in pharmaceutical wholesaling, dispensing pharmacy, manufacturing and sales of pharmaceuticals, and development and provision of customer support systems under the corporate slogan "Total Commitment to Good Health". TOHO HOLDINGS also proactively promotes initiatives for regional medical collaboration, nursing and home care.

Under the company philosophy "We contribute to the healthy lives of people through blazing a new path in the world of medicine", AMBICION works on research and development of the Natural Killer T (NKT) cell-targeted revolutionary new cancer immunotherapy and agent for allergic diseases, jointly with RIKEN.

Since TOHO HOLDINGS and AMBICION share the same philosophy, through this investment, TOHO HOLDINGS will collaborate in the sales and distribution of new and innovative therapeutics in Japan as well as support research and development of AMBICION.

2. Overview of AMBICION

- (1) Company name: AMBICION Co., Ltd.
- (2) Location: Wako Bldg. 5F, 2-6 Samoncho, Shinjuku-ku, Tokyo
- (3) Representative: Yoshiyuki Saito, CEO
- (4) Established: October 2015
- (5) Business content: Development of a new cancer immunotherapy and drug for treating allergic diseases targeting NKT cells

- (6) Capital: 1,562.41 million yen
- (7) Fiscal year end: December 31
- (8) Number of employees: 16
- (9) Contact: Yo Amakusa, in charge of public relations
(TEL: 81-3-5357-7231, FAX: 81-3-5357-7232)

3. Number of shares, method, price, shares owned before and after acquisition and share acquisition date

- (1) Number of shares to be acquired: 14,000 ordinary shares
- (2) Acquisition method: Subscription to third-party allotment of shares issued by AMBICION
- (3) Acquisition price: Undisclosed
- (4) Shares owned prior to acquisition: 0 (Ownership percentage: 0%)
- (5) Shares owned after acquisition: 14,000 (Ownership percentage: 8.38%)
- (6) Date of share acquisition: April 18, 2018

4. Forward looking outlook

Impact to consolidated performance is minor.